The Biocon TRADE group held its first research round-table in Cambridge MA, on Aug. 7 th and 8 th 2016. The meeting, focused on auto-immune and fibrotic disease, gathered together a distinguished group of academic and industry thought leaders to provide input and advice on the commercialization of maturing Biocon programs, with a particular emphasis on possible clinical trial design and disease markets. Biocon expects this meeting to be the blue-print for a series of annual diseases focused round-tables wherein disease experts in the US are exposed to Biocon programs in intensive focused settings.
Participants in Biocon Research Round-table in Autoimmune and Fibrotic disease, Cambridge, MA Aug 7-8th 2016:
The people are listed from left to right as they appear in the photo
Sunghoon Kim, PhD
Professor, College of Pharmacy and Director, Medicinal Bioconvergence Research Center (“Biocon”), Seoul National University
Robert Lafyatis, M.D.
Professor of Medicine and Thomas A. Medsger Endowed Professor of Scleroderma Research – University of Pittsburgh School of Medicine
Steven Ledbetter, PhD; formerly, Group Vice-President, Renal, Cardiovascular and Bone and Joint Diseases, Genzyme
Daniel Meruelo, PhD
Professor of Pathology and director of the Gene therapy Center, NYU
Robert Burrier, PhD
Chief Operating Officer and Vice-President Of Research and Development, Stemina Biomarker Discovery
Steven Burke, MD
Senior Vice President and Chief Medical Officer, Proteon Therapeutics, Inc.
Thomas X. Neenan, PhD
Chief Business Officer, Biocon and President of Excubio Pharmaceuticals
Neil Kirby, PhD CEO, Edimer Pharmaceuticals,
John R. MacDonald, PhD, DABT, formerly Senior VP R&D, MGI Pharma
Zihai Li, MD, PhD
Chairman and Professor, Department of Microbiology & Immunology Program Leader, Cancer Immunology Program Hollings Cancer Center Medical University of South Carolina (MUSC)